AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03465670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CHX+HA+ADS
Description: Patients received a 21-day supply of 0.2% chlorhexidine (CHX) containing 0.2% hyaluronic acid (HA) and Anti-Discoloration System (ADS) according to the randomization list, and were instructed to use 10 ml of the assigned mouthrinse for 1 minute, t.i.d. for 21 days. After rinsing, patients were asked to avoid washing their mouth or drinking for 30 minutes. Patients were asked to return the mouthrinse bottles (either empty of filled) at the end of the experimental period (day 21), in order to assess the level of patient compliance with the assigned CHX regimen.
Study NCT01699581 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nestle Impact Advanced Recovery
Description: dose of Nestle Impact Advanced Recovery orally three times a day beginning on the morning following stem cell transplant and continued until the day of hospital discharge.
Study NCT02477566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long-acting Triptorelin
Description: Pituitary down-regulation with Long-acting Triptorelin 1.875mg during the luteal phase
Study NCT02477566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Short-acting Triptorelin
Description: Pituitary down-regulation with Short-acting Triptorelin 0.1mg/d,x10d, then 0.05mg/d until E2\<40pg/ml in serum, was initiated during the luteal phase
Study NCT04152928 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MR scan
Description: The patient will be positioned in the PET/MR with the field of view of the PET including the abdomen, and IV administration of 68Ga-DOTATATE will take place, with initiation of dynamic PET simultaneous with start of IV injection. Dynamic PET imaging will consist of 22 time frames of increasing durations (6 x 10, 3 x 20, 3 x 60, 5 x 180, and 5 x 300 s). The dynamic PET examination will be followed by a whole-body PET/MR scan ranging from the proximal femur to the base of the skull (3 min per bed position) starting at 60 min after injection. MR will be used for attenuation correction of the PET images of the abdomen/pelvis and whole-body. MR protocol will include three plane fast spin echo T2 weighted, DWI, DCE and ASL. The addition of PET/MR to the standard use of PET/CT adds no radiation exposure.
Study NCT02243956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavanol rich food product
Description: polyphenol rich test product
Study NCT02243956 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Flavanol rich food product
Description: polyphenol rich test product
Study NCT01635985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5423
Description: solution for injection, administered as intravenous infusion Corr to total dose of 250 µg AZD5423
Study NCT01635985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5423
Description: nebuliser suspension, inhaled via Spira, corr to approximately 300 µg lung deposited dose AZD5423
Study NCT01635985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5423
Description: nebuliser suspension, inhaled via I-neb, corr to approximately 300 µg lung deposited dose AZD5423
Study NCT01635985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5423
Description: nebuliser suspension to be administered orally, corr to a total dose of 1200 µg AZD5423
Study NCT01635985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5423
Description: dry powder inhaled via Turbuhaler, corr to approximately 200 µg lung deposited dose AZD5423
Study NCT01635985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5423
Description: dry powder inhaled via New Dry Powder Inhaler, corr to approximately 200 µg lung deposited dose AZD5423
Study NCT04421222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Once daily dose of apalutamide
Study NCT03150511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesamorelin 2 Milligrams (MG)
Description: Daily self-administered study drug
Study NCT00695279 — intervention group
Intervention type: PROCEDURE
Intervention: Venipuncture
Description: Blood draw
Study NCT03155620 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT03831464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: The intervention will consist in IMP treatment during 30 months with half of the patients treated with Metformin Glucophage SR. Tablets of 500mg will be used at a dose of 2x500mg preferably taken during the evening meal.~During the first month of the trial a dose of 1x500mg will be used in order to avoid as much as possible some well-known mainly gastrointestinal side effects of metformin treatment .
Study NCT03831464 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: The intervention will consist in IMP treatment during 30 months with half of the patients treated with matched placebo. Tablets of 500mg will be used at a dose of 2x500mg preferably taken during the evening meal.
Study NCT04713254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG06466
Description: 10, 20, 30 mg/day oral capsules on Day 5-18
Study NCT04713254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 4 mg syrup, oral single dose on Day 1 and Day 15
Study NCT04713254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: 100 mg tablets, oral single dose on Day 1 and Day 15
Study NCT04713254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: 100 mg tablets, oral single dose on Day 3 and Day 17
Study NCT02810717 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: theta-burst stimulation using a MagPro X1000
Description: TBS over left and right dorsolateral prefrontal cortex for a period of three weeks. iTBS over left DLPFC: 3-pulse 50 Hz bursts will be given every 200ms (at 5 Hz) in 2-second trains with an inter-train interval of 8 seconds. Trains will be repeated 20 to reach a total number of 600 pulses per session. cTBS over right DLPFC: cTBS will comprise uninterrupted bursts to reach a total number of 600 pulses per session. Two sessions per day, separated by 60 minutes; 30 Sessions in total over 3 weeks.
Study NCT02810717 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation using a MagPro X1000
Description: Sham TBS with the coil set at 45° against the skull will be performed over left and right dorsolateral prefrontal cortex for a period of three weeks
Study NCT02145260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lower dialysate sodium (138 mmol/L; using Renasol hemodialysis concentrate)
Description: A lower dialysate sodium will bes used in the active comparator arm (138 mmol/L)
Study NCT02145260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Higher dialysate sodium (142 mmol/L; using Renasol hemodialysis concentrate)
Description: A higher dialysate sodium will be used in the experimental arm (142 mmol/L)
Study NCT01529788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Right lateral orbital injection of Botox Cosmetic or Dysport
Description: Right lateral orbital injection of Botox Cosmetic or Dysport (10 units and 30 units, respectively) divided among 4 injection points (0.05 mL \[7.5 units\] per injection point) divided among 4 injection points (0.05mL \[2.5units\]) on Day 0 of the study
Study NCT01529788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Left lateral orbital injection of Botox Cosmetic or Dysport
Description: Left lateral orbital injection of Botox Cosmetic or Dysport (10 units and 30 units, respectively) divided among 4 injection points (0.05 mL \[7.5 units\] per injection point) divided among 4 injection points (0.05mL \[2.5units\]) on Day 0 of the study
Study NCT02880280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Menopausal Gonadotropin
Description: Human Menopausal Gonadotropin injection treating congenital hypogonadotropic hypogonadism in teenagers
Study NCT02880280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Chorionic Gonadotropin
Description: Human Chorionic Gonadotropin injection treating congenital hypogonadotropic hypogonadism in teenagers
Study NCT03832517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single intravenous doses of RC-01
Description: Intravenous single escalating doses of RC-01
Study NCT03832517 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single intravenous doses of placebo
Description: Intravenous single doses of placebo to match RC-01
Study NCT03832517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multiple intravenous doses of RC-01
Description: Multiple ascending doses of RC-01 given intravenously two or three times daily for 10 days
Study NCT03832517 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Multiple intravenous doses of placebo
Description: Multiple doses of placebo to match RC-01 given intravenously two or three times daily for 10 days
Study NCT04905472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vestibular prosthesis/implant
Description: The intervention is a vestibular prosthesis which our collaborators at the University of Geneva are implanting into the inner ear in deaf patients without vestibular function who are receiving a cochlear implant. The vestibular implant (VI) has three rate sensors and senses angular head velocity in three dimensions and provides this information to the brain by stimulation the afferent nerves innervating the three semicircular canals. Our goal is to use the VI to better understand how the brain processes this prosthetic information and uses it to generate meaningful behavioral responses including eye movements, postural control, and perception.
Study NCT04905472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vestibular Implant Stimulation
Description: VI subjects will be studied before the implant is activated (pre) and then after it is turned on (acute On); this will take about 2 hrs. Then they will have 8 hours of motion-modulated VI stimulation while they actively explore the hospital environment, after studies will be repeated (chronic On). Each set of outcome experiments will be performed twice, once with and once without low-levels of stochastic noise added to the VI stimulation provided for the 8-hour period. The noise amplitude is tailored to each patient to maximize stochastic resonance so extraction \& integration of spatial signal provided by the VI will always be the first experiment, but the order of the subsequent outcome sessions (active/passive head rotations, tilt/translation motion discrimination and VOR behavioral changes \& postural control) will be randomized. VI subjects will participate in 4 full-day sessions, each separated by at least a month.
Study NCT01720654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EPT
Description: Standardized partner notification counseling and provision of 5 partner treatment packets containing: Printed information on signs, symptoms, diagnosis, and treatment of gonorrhea and chlamydia as well as information on local testing/treatment resources; 400 mg Cefixime and 1g Azithromycin.
Study NCT02615431 — intervention group
Intervention type: OTHER
Intervention: MitraClip Intervention
Study NCT03926364 — intervention group
Intervention type: OTHER
Intervention: Patients with referred pain
Description: The project does not affect treatment or does not offer any intervention.
Study NCT00200876 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Hypertonic saline
Description: To elicit pain
Study NCT00200876 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic saline
Description: To elicit pain
Study NCT00200876 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Isotonic saline
Description: Non-painful control
Study NCT00200876 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic saline
Description: Non-painful control
Study NCT03670446 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacists' intervention
Description: 1. Medication education: When the patient is enrolled in the intervention group, pharmacists issue an education manual to give a medical education which contains the reasons for using NOACs, the characteristics of the drug, the precautions, and how to monitor the efficacy. Pharmacists re-educate through telephone or clinic during follow-up.~2. Establish a medical record and remind their follow-up by message, phone every 2 weeks.~3. Follow-up in the 4th week and 8th week : Pharmacists recommend patients for drug therapy optimization after conducting a full pharmacotherapy review of each patient's medication regimen and remind them to test urinary occult blood every 1-3 months, detect hemoglobin and liver/kidney function every 3-6 months.
Study NCT03155620 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo a bone marrow and/or biopsy
Study NCT03155620 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo a bone scan
Study NCT03155620 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT, PET/Ct, and/or CT/MRI
Study NCT03155620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib
Description: Given PO
Study NCT03155620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Given PO
Study NCT03155620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Undergo molecular analysis
Study NCT03155620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotrectinib Sulfate
Description: Given PO or via nasogastric- or gastric-tube
Study NCT03155620 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI, PET/MRI, and/or CT/MRI
Study NCT03155620 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mutation Carrier Screening
Description: Undergo tumor tissue mutation screening
Study NCT03155620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT03155620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO
Study NCT03155620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00723008 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha Stim 100 (Cranial Electrotherapy Stimulation)
Description: cranial electrical stimulation 100 microamps
Study NCT03155620 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET, PET/CT, and/or PET/MRI
Study NCT03155620 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radionuclide Imaging
Description: Undergo radionuclide imaging
Study NCT03155620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samotolisib
Description: Given PO
Study NCT03155620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Given PO
Study NCT03155620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib Sulfate
Description: Given PO
Study NCT03155620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Given PO
Study NCT03155620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: Given PO or via nasogastric or gastric tube
Study NCT03155620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulixertinib
Description: Receive PO
Study NCT03155620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Given PO
Study NCT03155620 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo an x-ray
Study NCT04365504 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dual energy X ray absorbtiometry
Description: The primary clinical application of dual-energy x-ray absorptiometry (DXA or DEXA) is the measurement of bone mineral content (BMC, g) and bone mineral density (BMD, g/cm2) of the lumbar spine and proximal femur to assess risk for osteoporosis.
Study NCT02487810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive load
Description: Patients in the intuition arm of the study will be asked to complete a memorization task while they are answering survey questions.
Study NCT02487810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deliberative instructions
Description: Patients in the deliberative arm will be given instructions to take their time and deliberate on their decisions
Study NCT01302470 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary epicardial placement of left ventricular lead
Description: Epicardial leads will be placed on the left ventricle in the area of the most dyssynchrony . the leads will be attached to a Medtronic Cardiac resynchronization/ AICD/ device
Study NCT04886375 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spina plane block
Description: The investigators performed erector spina plane block to that patient group for postoperative analgesia
Study NCT04886375 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified pectoral nerve block
Description: The investigators performed modified pectoral block to that patient group for postoperative analgesia
Study NCT04669665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLS-002
Description: Intranasal racemic ketamine hydrochloride 90 milligrams (mg)
Study NCT04669665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intranasal placebo
Study NCT04669665 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Standard of care treatment will be determined by the treating physician(s) based on clinical judgement and practice guidelines
Study NCT04669665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of care treatment will be determined by the treating physician(s) based on clinical judgement and practice guidelines
Study NCT04669665 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal device
Description: Device to deliver intranasal solution
Study NCT04669665 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intranasal device
Description: Device to deliver intranasal solution
Study NCT04293666 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kefir
Description: 28 days supplementation kefir drink (prepared by inoculating pasteurized 9.2% reconstituted skim milk with powder kefir starter culture and fermented at 37 °C for 16 h. The fermented milk was then pasteurized at 100 °C for 30 min and freeze dried. The powder kefir starter culture used for inoculation was composed of defined lactic acid bacteria strains which contains Lactobacillus fermentum DSM 32784 (LF26), L. helveticus DSM 32787 (LH43), L. paracasei DSM 32785 (LPC12), L. rhamnosus DSM 32786 (LRH10), and Streptococcus thermophilus DSM 32788 (ST30)), 200ml/day
Study NCT04293666 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Maltodextrin, same calorie as kefir, 200ml/day
Study NCT00093964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilengitide 500 mg
Description: Subjects will receive 1-hour intravenous infusion of 500 mg cilengitide twice weekly on Day 1 and 4 of each week during every 4-week cycle, for a total of 8 infusions per cycle. Cycles were repeated without pause until progressive disease (PD), unacceptable adverse events (AEs), or withdrawal of consent.
Study NCT00093964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilengitide 2000 mg
Description: Subjects will receive 1-hour intravenous infusion of 2000 mg cilengitide twice weekly on Day 1 and 4 of each week during every 4-week cycle, for a total of 8 infusions per cycle. Cycles were repeated without pause until progressive disease (PD), unacceptable adverse events (AEs), or withdrawal of consent.
Study NCT01302470 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transvenous placement of left ventricular lead
Description: Conventional placement of left ventricular leads performed in the electrophysiology department.
Study NCT02740049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VR588
Description: Evaluation of the efficacy of a novel JAK/STAT inhibitor, VR588, in isolated epithelial cells from asthma patients
Study NCT03953963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HydraSolve T2D™
Description: The HydraSolve T2D™ System will be used to perform the combined minimally invasive laparoscopic and mini-laparotomy procedure to selectively extract excess intra-abdominal fat from the mesentery. All patients will receive standard nutritional counseling and their medications will be adjusted to achieve target levels of blood glucose control.
Study NCT01344668 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced Diabetes Education
Description: Provide enhanced diabetes education
Study NCT01344668 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Diabetes Education
Description: Provide Standard Diabetes Education
Study NCT02999828 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: inactivated EV71 vaccine (KMB-17)
Description: 3.0EU of inactivated enterovirus 71 vaccine (KMB-17) on day 0, 28.